A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
Author(s)
Somers, Joanna; Wilson, Lindsay A.; Kilday, John-Paul; Horvilleur, Emilie; Cobbold, Laura C.; Kondrashov, Alexander; Grill, Jacques; Grundy, Richard G.; Bushell, Martin; Willis, Anne E.; Poyry, Tuija A. A.; Puget, Stephanie; Knight, John R. P.; Cannell, Ian Gordon; ... Show more Show less
DownloadSomers-2015-A common polymorphis.pdf (966.1Kb)
PUBLISHER_CC
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
We show that a common polymorphic variant in the ERCC5 5′ untranslated region (UTR) generates an upstream ORF (uORF) that affects both the background expression of this protein and its ability to be synthesized following exposure to agents that cause bulky adduct DNA damage. Individuals that harbor uORF1 have a marked resistance to platinum-based agents, illustrated by the significantly reduced progression-free survival of pediatric ependymoma patients treated with such compounds. Importantly, inhibition of DNA-PKcs restores sensitivity to platinum-based compounds by preventing uORF1-dependent ERCC5 expression. Our data support a model in which a heritable 5′ noncoding mRNA element influences individuals’ responses to platinum-based chemotherapy.
Date issued
2015-09Department
Koch Institute for Integrative Cancer Research at MITJournal
Genes & Development
Publisher
Cold Spring Harbor Laboratory Press
Citation
Somers, Joanna, Lindsay A. Wilson, John-Paul Kilday, Emilie Horvilleur, Ian G. Cannell, Tuija A.A. Poyry, Laura C. Cobbold, et al. “A Common Polymorphism in the 5′ UTR of ERCC5 Creates an Upstream ORF That Confers Resistance to Platinum-Based Chemotherapy.” Genes Dev. 29, no. 18 (September 3, 2015): 1891–1896.
Version: Final published version
ISSN
0890-9369
1549-5477